Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu

And now Roche has received the first FDA approval for a companion diagnostic to identify patients carrying this HER2-low status—a more precise characterization of breast tumors that was previously more binary, relying largely on positive and negative labels.